se gb

Akinion Pharmaceuticals appoints Carl Harald Janson as CEO

STOCKHOLM, SWEDEN - January 9, 2012. Akinion Pharmaceuticals AB, a Karolinska Development AB portfolio company, announced today the appointment of Carl Harald Janson as new CEO. Carl Harald Janson, MD, PhD and CEFA, has over 25 years of experience in medicine, pharmaceutical development and asset management.

“We are very pleased to see Carl Harald Janson as new CEO in Akinion”, says Ingemar Aldén, Chairman of Akinion. “Carl Harald has been a board member of Akinion since its inception. His broad experience in pharmaceutical development will be of great benefit to the company.”
 
“I am much honored and excited to lead the experienced team of Akinion to take AKN-028 into clinical development stage. If the unique preclinical efficacy of AKN-028 translates into a comparable clinical benefit, then I am confident that AKN-028 could become a new important treatment for patients with acute myeloid leukemia”, says Carl Harald Janson, CEO, Akinion.
 
Carl Harald Janson served as Investment Manager at Karolinska Development from 2008 to 2011. He holds an MD and PhD from Karolinska Institutet and is a Certified European Financial Analyst (CEFA) from Stockholm School of Economics. Carl Harald has over 25 years of experience in medicine, pharmaceutical development and asset management including from Astra Arcus, Hagströmer & Qviberg Fondkommission, Danske Securities and Carnegie Investment Bank. He is currently Chairman of the Board of Dilaforette Holding and Board Director of Axelar, Oncopeptides, Clanotech and Akinion Pharmaceuticals.
 

For further information, please contact:
Ingemar Aldén, Chairman of Akinion Pharmaceuticals AB
Phone:  +46 (0) 70 530 84 82, e-mail: ingemar.alden@aldenco.se
 
 
 
TO THE EDITORS
 
About Akinion Pharmaceuticals AB
Akinion Pharmaceuticals AB is a Swedish biotech company founded in 2009. The company is developing kinase receptor inhibitors for treatment of acute myeloid leukemia. Akinion Pharmaceuticals is part of the Karolinska Development portfolio of companies. www.akinion.com
 
 
 
PDF.png Akinion Pharmaceuticals appoints Carl Harald Janson as CEO

2012-01-09